[2024/11/22] Gene and Cell Therapy- weekly digest from PackGene

Nov 22, 2024

Featured

Nov 21 Novartis buys Kate Therapeutics in $1.1B deal, eyes more bolt-on M&A read more »
Nov 18 Improved safety of chimeric antigen receptor T cells indirectly targeting antigens via switchable adapters read more »
Nov 18 Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis - Intellia Therapeutics read more »
Nov 18 Regenxbio starts pivotal study for DMD gene therapy read more »
Nov 18 Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference | Rocket Pharmaceuticals, Inc. read more »
Nov 14 PTC Therapeutics Announces FDA Approval of AADC Deficiency Gene Therapy | PTC Therapeutics, Inc. read more »
Nov 14 Ribozyme-activated mRNA trans-ligation enables large gene delivery to treat muscular dystrophies read more »
News
Nov 20 Vyriad announces strategic collaboration with Novartis to develop in vivo CAR-T cell therapies read more »
Nov 20 Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer read more »
Nov 19 Epigenic Therapeutics to Enter Clinical Development of EPI-003: A First-in-Class Epigenetic Inactivator for the Treatment of Chronic Hepatitis B read more »
Nov 14 Big Pharma's Next Move: BMS, Merck, Amgen Eye M&A to Tackle Patent Expirations read more »
Nov 13 Cell and Gene Therapy Market to Grow by USD 6.56 Billion (2024-2028), Driven by Rising Prevalence of Chronic Diseases, AI-Powered Report Explores Market Evolution - Technavio read more »
Articles
Nov 26 Engineered IscB-ωRNA system with improved base editing efficiency for disease correction via single AAV delivery in mice read more »
Nov 18 Rational strategies for improving the efficiency of design and discovery of nanomedicines | Nature Communications read more »
Nov 18 Dorsal root ganglion toxicity after AAV intra-CSF delivery of a RNAi expression construct into nonhuman primates and mice read more »
Nov 18 CRISPR targeting of mmu-miR-21a through a single adeno-associated virus vector prolongs survival of glioblastoma-bearing mice read more »
Nov 14 Intercellular nanotube-mediated mitochondrial transfer enhances T cell metabolic fitness and antitumor efficacy read more »
Nov 14 Profound cellular defects attribute to muscular pathogenesis in the rhesus monkey model of Duchenne muscular dystrophy read more »
Nov 13 Directed evolution of engineered virus-like particles with improved production and transduction efficiencies read more »
Nov 12 A framework for N-of-1 trials of individualized gene-targeted therapies for genetic diseases | Nature Communications read more »
Nov 12 Multimodal scanning of genetic variants with base and prime editing read more »
Nov 11 Split-design approach enhances the therapeutic efficacy of ligand-based CAR-T cells against multiple B-cell malignancies read more »
Nov 11 Optimizing CAR-T Treatment: A T2EVOLVE Guide to Raw and Starting Material Selection read more »
Nov 08 Binding-driven forward tearing protospacer activated CRISPR-Cas12a system and applications for microRNA detection read more »
Nov 07 Engineered PsCas9 enables therapeutic genome editing in mouse liver with lipid nanoparticles read more »
Nov 06 AAVrh.10 Delivery of Novel APOE2-Christchurch Variant Suppresses Amyloid and Tau Pathology in Alzheimer’s Disease Mice read more »

PackGene’s Newsletter

Receive the latest news and insights to your inbox.

Subscribe Now
About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Related News

Related Services

AAV Packaging Services

We have developed a series of proprietary technologies that greatly improve AAV production outcomes including titer, purity, potency, and consistency.

READ MORE

Off-the-Shelf AAV Products

We offer a library of carefully designed and pre-stocked AAV vectors for a wide variety of experimental needs.

READ MORE